(LTRN) – StreetInsider.com Reports
-
Lantern Pharma (LTRN) Tops Q4 EPS by 1c
-
Lantern Pharma's (LTRN) Starlight Therapeutics Appoints Marc Chamberlain as Chief Medical Officer
-
Lantern Pharma (LTRN) Tops Q3 EPS by 19c
-
Lantern Pharma (LTRN) Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
-
Lantern Pharma (LTRN) Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
-
Lantern Pharma (LTRN) Tops Q2 EPS by 2c
-
Lantern Pharma (LTRN) Receives FDA Clearance of IND Application for Drug Candidate LP-184
-
Lantern Pharma (LTRN) Leverages RADR to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
-
EF Hutton Assumes Lantern Pharma Inc. (LTRN) at Buy
-
H.C. Wainwright Starts Lantern Pharma Inc. (LTRN) at Neutral, 'Waiting for Harmonic Data on the Sidelines'
-
Lantern Pharma (LTRN) Tops Q1 EPS by 12c
-
Lantern Pharma (LTRN) Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
-
Lantern Pharma (LTRN) Tops Q4 EPS by 16c
-
Lantern Pharma (LTRN) Has No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank
-
Lantern Pharma (LTRN) Announces New Data and Development Focus for LP-100 with PARP Inhibitors
-
Lantern Pharma (LTRN) Granted FDA Orphan Drug Designation for LP-284
-
Lantern Pharma (LTRN) Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium
-
EF Hutton Starts Lantern Pharma Inc. (LTRN) at Buy
-
Lantern Pharma (LTRN) Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300
-
Lantern Pharma (LTRN) to Present Positive Preclinical Data on the Efficacy of LP-284
-
Lantern Pharma (LTRN) Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
-
Lantern Pharma (LTRN) Appoints Maria Maccecchini to its Board
-
Lantern Pharma (LTRN) Announces Extension of Existing Share Repurchase Program
-
Lantern Pharma Inc. (LTRN) PT Raised to $36 at H.C. Wainwright
-
Lantern Pharma (LTRN) Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor
-
Lantern Pharma (LTRN) Enters Collaboration & Research Agreement with The Danish Cancer Society Research Center for Development of LP-100 and LP-184, in Solid Tumors
-
Lantern Pharma (LTRN) Expands Oncology Collaboration with the National Cancer Institute
-
Lantern Pharma (LTRN) Reports Positive Efficacy Data of LP-284 in Hematologic Cancers
-
Lantern Pharma (LTRN) Announces $7M Share Buyback
-
Lantern Pharma Inc. (LTRN) PT Raised to $34 at H.C. Wainwright
-
H.C. Wainwright Starts Lantern Pharma Inc. (LTRN) at Buy
-
Lantern Pharma (LTRN) Enters into Strategic Collaboration with Deep Lens
-
Pre-Open Stock Movers 08/30: (GSAT) (AFRM) (DSPG) Higher; (EAT) (PLAY) (COF) Lower (more...)
-
Lantern Pharma (LTRN) Granted FDA Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas
-
Lantern Pharma (LTRN) Announces FDA Grants it Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
-
Lantern Pharma (LTRN) Tops Q2 EPS by 5c
-
Lantern Pharma (LTRN) Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
-
Pre-Open Stock Movers 07/20: (IMNM) (NURO) (PTON) Higher; (ARDX) (PPG) (RKT) Lower (more...)
-
Lantern Pharma (LTRN) Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
-
Lantern Pharma (LTRN) Files $200M Mixed Shelf
-
Lantern Pharma (LTRN) Tops Q1 EPS by 3c
-
Lantern Pharma (LTRN), Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform
-
Lantern Pharma (LTRN) Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget
-
Lantern Pharma (LTRN) to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021
-
Lantern Pharma (LTRN) Misses Q4 EPS by 2c
-
Lantern Pharma (LTRN) Prices 4.28M Share IPO at $14/Sh
-
Lantern Pharma (LTRN) Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers
-
Lantern Pharma (LTRN) Reports Advancement of Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184
-
Lantern Pharma (LTRN) Announces Pact with Fox Chase Cancer Center Focused on Advancing Development of LP-184 in Pancreatic Cancer
-
Lantern Pharma (LTRN) Reports Q2 Loss of $0.31
Back to LTRN Stock Lookup